Breaking WORLD PHARMA NEWS

U.S. FDA approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older.

Read more …

Bayer launches unit to develop new precision health consumer products

The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.

Read more …

Researchers use ‘natural’ system to identify proteins most useful for developing an effective HIV vaccine

Since it was identified in 1984 as the cause of Acquired Immune Deficiency Syndrome (AIDS), the human immunodeficiency virus (HIV) has infected more than 80 million people and been responsible for some 40 million deaths worldwide, according to the World Health Organization (WHO). Currently, the WHO reports more than 38 million people globally live with the retrovirus, and each year, another 1 million new cases are diagnosed.

Read more …

New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer's disease

Why do some people develop Alzheimer's disease while others don't? And, even more puzzlingly, why do many individuals whose brains are chock-full of toxic amyloid aggregates - a telltale sign of Alzheimer's brain pathology - never go on to develop Alzheimer's-associated dementias?

University of Pittsburgh School of Medicine researchers appear to have found the answer.

Read more …

Large study provides scientists with deeper insight into long COVID symptoms

Initial findings from a study of nearly 10,000 Americans, many of whom had COVID-19, have uncovered new details about long COVID, the post-infection set of conditions that can affect nearly every tissue and organ in the body. Clinical symptoms can vary and include fatigue, brain fog, and dizziness, and last for months or years after a person has COVID-19. The research team, funded by the National Institutes of Health, also found that long COVID was more common and severe in study participants infected before the 2021 Omicron variant.

Read more …

Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID has been available in the U.S. since December 2021 under Emergency Use Authorization (EUA), and the overall benefit/risk profile and indication for use in eligible adults remain consistent with the EUA.

Read more …

Multivitamin improves memory in older adults, study finds

Taking a daily multivitamin supplement can slow age-related memory decline, finds a large study led by researchers at Columbia University and Brigham and Women's Hospital/Harvard.

"Cognitive aging is a top health concern for older adults, and this study suggests that there may be a simple, inexpensive way to help older adults slow down memory decline,"

Read more …

Capturing transporter structure paves the way for drug development

Scientists at St. Jude Children’s Research Hospital and the University of Texas Southwestern Medical Center studied the structure and function of a transporter involved in cancer and immunity. They captured six structures of the transporter, including when it was bound to an inhibitor, providing unprecedented insight into how it works. The findings, published in Cell, have implications for drug development.

Read more …

Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI

Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that the company has nominated a potentially best-in-class preclinical candidate targeting ENPP1 for cancer immunotherapy and the potential treatment of Hypophosphatasia (HPP).

ENPP1 is an ecto-nucleotide pyrophosphatase that plays an important role in purinergic signaling that regulates immune, cardiovascular, neurological, and hematological system functions.

Read more …

FDA Advisory Committee votes in support of approval for Pfizer's vaccine candidate to help prevent RSV in infants through maternal immunization

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the available data support the efficacy and safety of its unadjuvanted bivalent respiratory syncytial virus (RSV) prefusion F vaccine candidate RSVpreF or PF-06928316.

Read more …